Viewing Study NCT06208150


Ignite Creation Date: 2025-12-24 @ 5:12 PM
Ignite Modification Date: 2025-12-26 @ 3:15 PM
Study NCT ID: NCT06208150
Status: RECRUITING
Last Update Posted: 2025-12-19
First Post: 2024-01-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Sponsor: Janssen Research & Development, LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module